NI202000017A - PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ACCOMPANIED BY DIABETES, INCLUDING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND A COMPOSITE PREPARATION INCLUDING THE SAME - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ACCOMPANIED BY DIABETES, INCLUDING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND A COMPOSITE PREPARATION INCLUDING THE SAME

Info

Publication number
NI202000017A
NI202000017A NI202000017A NI202000017A NI202000017A NI 202000017 A NI202000017 A NI 202000017A NI 202000017 A NI202000017 A NI 202000017A NI 202000017 A NI202000017 A NI 202000017A NI 202000017 A NI202000017 A NI 202000017A
Authority
NI
Nicaragua
Prior art keywords
pharmaceutical composition
losartan
rosuvastatin
diabetes
prevention
Prior art date
Application number
NI202000017A
Other languages
Spanish (es)
Inventor
A Jung Jin
Yung Bae Hye
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66174145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI202000017(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of NI202000017A publication Critical patent/NI202000017A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan en la presente una composición farmacéutica para la prevención o el tratamiento de una enfermedad cardiovascular acompañada por diabetes, y una preparación compuesta que incluye la composición farmacéutica. La composición farmacéutica incluye amlodipino o una sal farmacéuticamente aceptable del mismo, losartán o una sal farmacéuticamente aceptable del mismo y rosuvastatina o una sal farmacéuticamente aceptable de la misma.Provided herein are a pharmaceutical composition for the prevention or treatment of cardiovascular disease accompanied by diabetes, and a composite preparation that includes the pharmaceutical composition. The pharmaceutical composition includes amlodipine or a pharmaceutically acceptable salt thereof, losartan or a pharmaceutically acceptable salt thereof, and rosuvastatin or a pharmaceutically acceptable salt thereof.

NI202000017A 2017-10-17 2020-02-28 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ACCOMPANIED BY DIABETES, INCLUDING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND A COMPOSITE PREPARATION INCLUDING THE SAME NI202000017A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170134809 2017-10-17
KR1020180112376A KR20190043076A (en) 2017-10-17 2018-09-19 Pharmaceutical composition comprising amlodipine, losartan and rosuvastatin for prevention and treatment of cardiovascular diseases accompanied by diabetes and formulated combination including the same

Publications (1)

Publication Number Publication Date
NI202000017A true NI202000017A (en) 2020-03-18

Family

ID=66174145

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202000017A NI202000017A (en) 2017-10-17 2020-02-28 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ACCOMPANIED BY DIABETES, INCLUDING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND A COMPOSITE PREPARATION INCLUDING THE SAME

Country Status (12)

Country Link
KR (1) KR20190043076A (en)
CN (1) CN111511369A (en)
CO (1) CO2020001514A2 (en)
CR (1) CR20200096A (en)
EA (1) EA202090165A1 (en)
EC (1) ECSP20014155A (en)
MX (1) MX2020001681A (en)
NI (1) NI202000017A (en)
PH (1) PH12020500295A1 (en)
SG (1) SG11202000622WA (en)
TW (1) TW201922243A (en)
WO (1) WO2019078592A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021251644A1 (en) * 2020-06-09 2021-12-16 한미약품 주식회사 Complex pharmaceutical preparation, for preventing or treating cardiovascular disease, comprising amlodipine, losartan and chlorthalidone in single-layer tablet

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100742432B1 (en) 2005-12-27 2007-07-24 한미약품 주식회사 Complex formulation comprising amlodipine camsylate and simvastatin, and method for preparation thereof
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.
SI2136798T1 (en) * 2007-03-21 2015-10-30 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
KR101207618B1 (en) * 2008-02-22 2012-12-04 한올바이오파마주식회사 Pharmaceutical formulation for treating cardiovascular disease
KR101910901B1 (en) * 2013-11-29 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
CN108156807A (en) * 2015-06-30 2018-06-12 韩美药品株式会社 Medicine compound preparation containing Amlodipine, Losartan and Rosuvastatin

Also Published As

Publication number Publication date
CR20200096A (en) 2020-04-03
WO2019078592A1 (en) 2019-04-25
CN111511369A (en) 2020-08-07
CO2020001514A2 (en) 2020-02-28
ECSP20014155A (en) 2020-04-22
SG11202000622WA (en) 2020-02-27
MX2020001681A (en) 2020-07-13
EA202090165A1 (en) 2020-07-10
KR20190043076A (en) 2019-04-25
PH12020500295A1 (en) 2020-11-09
TW201922243A (en) 2019-06-16

Similar Documents

Publication Publication Date Title
SV2018005682A (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
CL2017000782A1 (en) Mono- or disubstituted indole derivatives as inhibitors of dengue virus replication
CL2018002758A1 (en) Indoline derivatives substituted as inhibitors of dengue viral replication.
CL2019002745A1 (en) Substituted indoline derivatives as dengue virus replication inhibitors.
CL2018002718A1 (en) Indoline derivatives substituted as inhibitors of dengue viral replication.
CL2019002744A1 (en) Substituted indoline derivatives as dengue virus replication inhibitors.
CL2017001904A1 (en) Composition for the treatment of hepatic veno-occlusive disease.
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
AR094707A1 (en) COMPOUND OF QUINAZOLIN-4-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE TREATMENT OF A DISEASE MEDIATED BY THE RIP2 KINASE
CO2017007076A2 (en) Indenyl compounds, pharmaceutical compositions and medical uses thereof
CR20170314A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
MX2020003732A (en) Fused ring derivative as a.
UY36124A (en) CARBOXAMIDE DERIVATIVES
CL2015002466A1 (en) Organic compound formulations
CR20160529A (en) PHARMACEUTICAL COMPOSITIONS TO TREAT INFECTIOUS DISEASES
DOP2016000161A (en) ASYMMETRIC UREAS P- SUBSTITUTED AND MEDICAL USES OF THE SAME.
NI202000017A (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ACCOMPANIED BY DIABETES, INCLUDING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND A COMPOSITE PREPARATION INCLUDING THE SAME
CR20170125A (en) SOLID PHARMACEUTICAL COMPOSITION INCLUDING AMLODIPINA AND LOSARTÁN
AR103219A1 (en) COMPOSITE OF (1H-INDOL-3-IL) PROPAN-1-ONA, PHARMACEUTICAL COMPOSITION, COMBINATION AND MIXTURE THAT INCLUDE IT AND ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR109209A1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES
BR112018006206A2 (en) composition, use of a combination, pharmaceutical fixed dosage form, fixed dosage combination, packaging, and use of a fixed dose combination
CU20180036A7 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
CL2017000026A1 (en) Pharmaceutical dosage forms
AR106645A1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS